Cell-based tolerogenic therapy, experience from animal models of multiple sclerosis, type 1 diabetes and rheumatoid arthritis

Ivana Stojanović, Mirjana Dimitrijević, Marta Vives-Pi, María José Mansilla, Irma Pujol-Autonell, Silvia Rodríguez-Fernandez, Lenka Palová-Jelínková, David P. Funda, Alisa Gruden-Movsesijan, Ljiljana Sofronić-Milosavljević, Catharien M.U. Hilkens, Eva Martinez Caceres, Djordje Miljković

Research output: Contribution to journalReview articleResearchpeer-review

8 Citations (Scopus)

Abstract

© 2017 Bentham Science Publishers. Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Original languageEnglish
Pages (from-to)2623-2643
JournalCurrent Pharmaceutical Design
Volume23
Issue number18
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Cell-based tolerogenic therapy
  • Multiple sclerosis
  • Regulatory T cells
  • Rheumatoid arthritis
  • Tolerogenic dendritic cells
  • Type 1 diabetes

Fingerprint Dive into the research topics of 'Cell-based tolerogenic therapy, experience from animal models of multiple sclerosis, type 1 diabetes and rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this